714249-80-6

Basic information

• Product Name: 2'-C-methyl-6-O-methyl-guanosine
• Synonyms: 2'-C-methyl-6-O-methyl-guanosine;(2R,3R,4R,5R)-2-(2-AMino-6-Methoxy-9H-purin-9-yl)-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-3,4-diol;2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-3-methyl-tetrahydro-furan-3,4-diol;EOS-60514
• CAS NO: 714249-80-6
• Molecular Formula: C₁₂H₁₇N₅O₅
• Molecular Weight: 311.2974
• Mol File: 714249-80-6.mol

Chemical Properties

• Boiling Point: 690.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.82
• PKA: 13.13±0.70(Predicted)
• CAS DataBase Reference: 2'-C-methyl-6-O-methyl-guanosine(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-C-methyl-6-O-methyl-guanosine(714249-80-6)
• EPA Substance Registry System: 2'-C-methyl-6-O-methyl-guanosine(714249-80-6)

Safety Data

• Hazardous Substances Data: 714249-80-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Biochemical Research:
2'-C-methyl-6-O-methyl-guanosine is utilized as a research compound for its potential anti-viral activity, making it a candidate for the development of new antiviral therapies. Its stability and resistance to degradation contribute to its effectiveness in this application.
Used in Nucleic Acid Analogs:
2'-C-methyl-6-O-methyl-guanosine serves as a building block for the synthesis of nucleic acid analogs with improved properties. The modifications to the guanosine structure allow for the creation of analogs that may offer enhanced performance in various biological assays and therapeutic applications.
Used in Molecular Probes for RNA Research:
2'-C-methyl-6-O-methyl-guanosine is employed as a molecular probe to study the structure and function of RNA. Its modified structure allows researchers to gain insights into RNA biology, which can be crucial for understanding RNA's role in various cellular processes and diseases.

Upstream product

• 10310-21-1 2-Amino-6-chloropurin 
• 67-56-1 methanol 
• 641571-44-0 (2R,3R,4R,5R)-2-(2-amino-6-chloro-9H-purin-9-yl)-5-(benzoyloxymethyl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate 
• 10310-21-1 2-amino-6-chloropurine 
• 124-41-4 sodium methylate 
• 15397-15-6 1,2,3,5-tetra-O-benzoyl-2-C-methyl-β-D-ribofuranose 

Downstream Products

• 1234491-54-3 (2R,3R,4R,5R)-2-(2-(4-fluorobenzylamino)-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 
• 1234490-75-5 benzyl (2S)-(((2R,3R,4R,5R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy(naphthalene-1-yloxy)phosphorylamino)propanoate 
• 1234490-83-5 INX-08189 
• 1350765-85-3 (2S)-benzyl 2-((((2R,3R,4R,5R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(butylamino)phosphorylamino)propanoate 
• 1384068-28-3 benzyl 2(S)-(((2R,3R,4R,5R)-5-(2-amino-8-iodo-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy(naphthalene-1-yloxy)phosphorylamino)propanoate 
• 1384068-42-1 (2S,2'S)-benzyl 2,2'-((((2R,3R,4R,5R)-5-(2-amino-8-iodo-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)phosphoryl)bis(azanediyl)dipropanoate 
• 1427287-70-4 C₃₀H₄₃FN₇O₁₀P 
• 1427287-73-7 C₂₆H₃₅N₆O₁₁P 
• 1604813-52-6 C₃₈H₄₈N₁₂O₁₄P₂ 
• 1604813-47-9 C₄₁H₅₁FN₁₂O₁₃P₂ 
• 1604813-50-4 C₃₉H₄₉FN₁₂O₁₃P₂ 

Relevant articles and documents

Synthesis of 2′-Methyl-6-methoxyguanosine from the Parent Ribonucleoside Guanosine

A short and efficient synthesis of the nucleoside fragment contained in the NS5B nucleoside inhibitor BMS-986094 was achieved in 23% overall yield on a gram scale. The synthesis uses the widely available starting material guanosine via a short sequence ending in a Mukaiyama hydration reaction to establish the key tertiary alcohol moiety and set the C-2′ methyl stereogenic center. This work resulted in a robust and scalable approach to this complex nucleoside.

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in com

O-(substituted benzyl) phosphoramidate compounds and therapeutic use

This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and canc

CRYSTALLINE SOLVATES OF NUCLEOSIDE PHOSPHOROAMIDATES, THEIR STEREOSELECTIVE PREPARATION, NOVEL INTERMEDIATES THEREOF, AND THEIR USE IN THE TREATMENT OF VIRAL DISEASE

This invention is directed to novel crystalline solvates of the (S)-P diastereomer of the anti- HCV nucleoside phosphoroamidate, (2S)-neopentyl 2-((((2R,3R,4R,5R)-5-(2-amino-6- methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(nap

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS

This invention is directed to novel compounds of formula (I) having the structure (I) wherein U, V, W, Z, R 1, X1, X2, and Y are defined herein. The compounds of formula (I) and pharmaceutical compositions containing these

PHOSPHORODIAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INJECTIONS

This invention is directed to novel compounds of formula (I) having the structure that are useful in the treatment of viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses. Methods of treating viral infec

Dual pro-drugs of 2′-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus

We have previously reported the power of combining a 5′- phosphoramidate ProTide, phosphate pro-drug, motif with a 6-methoxy purine pro-drug entity to generate highly potent anti-HCV agents, leading to agents in clinical trial. We herein extend this work with the disclosure that a variety of alternative 6-substituents are tolerated. Several compounds exceed the potency of the prior 6-methoxy leads, and in almost every case the ProTide is several orders of magnitude more potent than the parent nucleoside. We also demonstrate that these agents act as pro-drugs of 2′-C-methyl guanosine monophosphate. We have also reported the novel use of hepatocyte cell lysate as an ex vivo model for ProTide metabolism.

PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS

Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus

We herein report a novel double pro-drug approach applied to the anti-HCV agent 2′-β-C-methyl guanosine. A phosphoramidate ProTide motif and a 6-O-methoxy base pro-drug moiety are combined to generate lipophilic prodrugs of the monophosphate of the guanin